IL-17A抑制减轻实验性脊柱关节炎的炎症与新骨形成
该研究在体外用脊柱关节炎(SpA)成纤维样滑膜细胞(FLS)测试TNF和IL-17A对成骨分化的影响,并在HLA-B27/hβ2m转基因大鼠中预防性和治疗性阻断IL-17A。结果显示TNF和IL-17A显著促进成骨分化;预防性和治疗性抗IL-17A均减轻炎症和新骨形成,提示IL-17A驱动炎症与病理新骨形成的直接关联。
要点
- TNF和IL-17A均可显著增加SpA FLS的体外成骨分化。
- 预防性抗IL-17A延缓脊柱炎和关节炎发生并减轻严重度。
- 治疗性抗IL-17A减少轴性和外周关节炎症及结构损伤。
核心结论
- 预防性和治疗性抑制IL-17A均可减轻HLA-B27/hβ2m转基因大鼠的炎症和新骨形成。
- IL-17A促进人SpA FLS成骨分化,提示IL-17A驱动的炎症与病理新骨形成直接关联。
研究设计与样本
- 体外用SpA FLS在地塞米松、β-甘油磷酸酶和抗坏血酸条件下行成骨分化实验,测试TNF和IL-17A的影响。
- 在HLA-B27/hβ2m转基因大鼠SpA模型中行预防性和治疗性IL-17A阻断。
- 通过micro-CT成像、组织学分析和基因表达谱评估炎症和新骨形成。
主要发现
- TNF和IL-17A显著增加体外成骨细胞分化。
- 预防性IL-17A阻断显著延缓脊柱炎和关节炎发展并降低关节炎严重度。
- 抗IL-17A治疗与预防骨丢失和骨膜新骨形成相关。
- 初始炎症损伤后治疗性靶向IL-17A也显著减少轴性和外周关节炎症。
- 治疗性抗IL-17A显著减少脊柱和外周结构损伤包括新骨形成,RNA测序证实其逆转炎症特征和骨损伤相关基因表达。
临床怎么用
- 在SpA模型中,IL-17A阻断在预防和治疗设置下均减轻炎症和结构损伤,支持IL-17A作为炎症与新骨形成的共同驱动因子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: It remains unclear if and how inflammation and new bone formation in spondyloarthritis (SpA) are coupled. We undertook this study to assess the hypothesis that interleukin-17A (IL-17A) is a pivotal driver of both processes. METHODS: The effect of tumor necrosis factor (TNF) and IL-17A on osteogenesis was tested in an osteoblastic differentiation assay using SpA fibroblast-like synoviocytes (FLS) differentiated with dexamethasone, β-glycophosphatase, and ascorbic acid. IL-17A blockade was performed in HLA-B27/human β2 -microglobulin (hβ2 m)-transgenic rats, which served as a model for SpA in both prophylactic and therapeutic settings. Inflammation and new bone formation were evaluated by micro-computed tomography imaging, histologic analysis, and gene expression profiling. RESULTS: TNF and IL-17A significantly increased in vitro osteoblastic differentiation. In vivo, prophylactic blockade of IL-17A significantly delayed spondylitis and arthritis development and decreased arthritis severity. Anti-IL-17A treatment was also associated with prevention of bone loss and periosteal new bone formation. Therapeutic targeting of IL-17A after the initial inflammatory insult also significantly reduced axial and peripheral joint inflammation. This treatment was again associated with a marked reduction in spinal and peripheral structural damage, including new bone formation. RNA sequencing of target tissue confirmed that IL-17A is a key driver of the molecular signature of disease in this model and that therapeutic anti-IL-17A treatment reversed the inflammatory signature and the selected gene expression related to bone damage. CONCLUSION: Both prophylactic and therapeutic inhibition of IL-17A diminished inflammation and new bone formation in HLA-B27/hβ2 m-transgenic rats. Taken together with the ability of IL-17A to promote osteoblastic differentiation of human SpA FLS, these data suggest a direct link between IL-17A-driven inflammation and pathologic new bone formation in SpA.
引用
- van Tok MN, van Duivenvoorde LM, Kramer I, et al. Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis. Arthritis Rheumatol. 2019. PMID: 30390386. doi:10.1002/art.40770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。